 | |
| Clinical data | |
|---|---|
| Other names | αP-VTHNa2; Tetralin-α-PVP; α-Propyl-β-ketotetralinylethylpyrrolidine |
| Drug class | Monoamine reuptake inhibitor |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C19H27NO |
| Molar mass | 285.431 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
TH-PVP is asubstituted cathinone derivative which has been sold as adesigner drug. It was first identified by a forensic laboratory in Hungary in 2015,[2] but has subsequently been found in numerous other countries around the world including Spain, Belgium, Poland, Turkey and Brazil.[3][4][5][6][7][8]
Pharmacological studiesin vitro showed it toinhibitreuptake of themonoamine neurotransmitters, with about 10-foldselectivity forserotonin overnorepinephrine anddopamine, whereas the drug did notinduce monoamine release.[9] A subsequent study found that it showed similarpotency for serotonin and dopamine but was markedly selective for reuptake inhibition of these neurotransmitters over norepinephrine..[10] Despite its activity as amonoamine reuptake inhibitor, TH-PVP failed to producestimulant effects in animals.[11]
